6F3Y

Backbone structure of Des-Arg10-Kallidin (DAKD) peptide bound to human Bradykinin 1 Receptor (B1R) determined by DNP-enhanced MAS SSNMR

SOLID-STATE NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 13C-13C DQ-SQ	312.5 uM [U-13C; U-15N] K1 Des-Arg10-Kallidin (DAKD), 312.5 uM not labeled human B1R, 10 mM not labeled AMUPOL, 50 mM not labeled HEPES, 150 mM not labeled NaCl, 4 % w/v not labeled DDM, 0.4 % w/v not labeled CHS	10% H2O/ 40%D2O/ 50% d8-glycerol	175 mM	7.6	1 atm	110	Bruker AVANCE II 400
2	2D 15N-13C TEDOR	312.5 uM [U-13C; U-15N] K1 Des-Arg10-Kallidin (DAKD), 312.5 uM not labeled human B1R, 10 mM not labeled AMUPOL, 50 mM not labeled HEPES, 150 mM not labeled NaCl, 4 % w/v not labeled DDM, 0.4 % w/v not labeled CHS	10% H2O/ 40%D2O/ 50% d8-glycerol	175 mM	7.6	1 atm	110	Bruker AVANCE II 400
3	2D 13C-13C DQ-SQ	312.5 uM [U-13C; U-15N] R2S7 Des-Arg10-Kallidin (DAKD), 312.5 uM not labeled human B1R, 10 mM not labeled AMUPOL, 50 mM not labeled HEPES, 150 mM not labeled NaCl, 4 % w/v not labeled DDM, 0.4 % w/v not labeled CHS	10% H2O/ 40%D2O/ 50% d8-glycerol	175 mM	7.6	1 atm	110	Bruker AVANCE II 400
4	2D 15N-13C TEDOR	312.5 uM [U-13C; U-15N] R2S7 Des-Arg10-Kallidin (DAKD), 312.5 uM not labeled human B1R, 10 mM not labeled AMUPOL, 50 mM not labeled HEPES, 150 mM not labeled NaCl, 4 % w/v not labeled DDM, 0.4 % w/v not labeled CHS	10% H2O/ 40%D2O/ 50% d8-glycerol	175 mM	7.6	1 atm	110	Bruker AVANCE II 400
5	2D 13C-13C DQ-SQ	312.5 uM [U-13C; U-15N] P3 Des-Arg10-Kallidin (DAKD), 312.5 uM not labeled human B1R, 10 mM not labeled AMUPOL, 50 mM not labeled HEPES, 150 mM not labeled NaCl, 4 % w/v not labeled DDM, 0.4 % w/v not labeled CHS	10% H2O/ 40%D2O/ 50% d8-glycerol	175 mM	7.6	1 atm	110	Bruker AVANCE II 400
9	2D 15N-13C TEDOR	312.5 uM [U-13C; U-15N] P3 Des-Arg10-Kallidin (DAKD), 312.5 uM not labeled human B1R, 10 mM not labeled AMUPOL, 50 mM not labeled HEPES, 150 mM not labeled NaCl, 4 % w/v not labeled DDM, 0.4 % w/v not labeled CHS	10% H2O/ 40%D2O/ 50% d8-glycerol	175 mM	7.6	1 atm	110	Bruker AVANCE II 400
8	2D 13C-13C DQ-SQ	312.5 uM [U-13C; U-15N] P4 Des-Arg10-Kallidin (DAKD), 312.5 uM not labeled human B1R, 10 mM not labeled AMUPOL, 50 mM not labeled HEPES, 150 mM not labeled NaCl, 4 % w/v not labeled DDM, 0.4 % w/v not labeled CHS	10% H2O/ 40%D2O/ 50% d8-glycerol	175 mM	7.6	1 atm	110	Bruker AVANCE II 400
7	2D 15N-13C TEDOR	312.5 uM [U-13C; U-15N] P4 Des-Arg10-Kallidin (DAKD), 312.5 uM not labeled human B1R, 10 mM not labeled AMUPOL, 50 mM not labeled HEPES, 150 mM not labeled NaCl, 4 % w/v not labeled DDM, 0.4 % w/v not labeled CHS	10% H2O/ 40%D2O/ 50% d8-glycerol	175 mM	7.6	1 atm	110	Bruker AVANCE II 400
6	2D 13C-13C DQ-SQ	312.5 uM [U-13C; U-15N] G5F6 Des-Arg10-Kallidin (DAKD), 312.5 uM not labeled human B1R, 10 mM not labeled AMUPOL, 50 mM not labeled HEPES, 150 mM not labeled NaCl, 4 % w/v not labeled DDM, 0.4 % w/v not labeled CHS	10% H2O/ 40%D2O/ 50% d8-glycerol	175 mM	7.6	1 atm	110	Bruker AVANCE II 400
10	2D 15N-13C TEDOR	312.5 uM [U-13C; U-15N] G5F6 Des-Arg10-Kallidin (DAKD), 312.5 uM not labeled human B1R, 10 mM not labeled AMUPOL, 50 mM not labeled HEPES, 150 mM not labeled NaCl, 4 % w/v not labeled DDM, 0.4 % w/v not labeled CHS	10% H2O/ 40%D2O/ 50% d8-glycerol	175 mM	7.6	1 atm	110	Bruker AVANCE II 400
11	2D 13C-13C DQ-SQ	312.5 uM [U-13C; U-15N] S7P9 Des-Arg10-Kallidin (DAKD), 312.5 uM not labeled human B1R, 10 mM not labeled AMUPOL, 50 mM not labeled HEPES, 150 mM not labeled NaCl, 4 % w/v not labeled DDM, 0.4 % w/v not labeled CHS	10% H2O/ 40%D2O/ 50% d8-glycerol	175 mM	7.6	1 atm	110	Bruker AVANCE II 400
13	2D 13C-13C DQ-SQ	312.5 uM [U-13C; U-15N] S7P9 Des-Arg10-Kallidin (DAKD), 312.5 uM not labeled human B1R, 10 mM not labeled AMUPOL, 50 mM not labeled HEPES, 150 mM not labeled NaCl, 4 % w/v not labeled DDM, 0.4 % w/v not labeled CHS	10% H2O/ 40%D2O/ 50% d8-glycerol	175 mM	7.6	1 atm	110	Bruker AVANCE II 400
12	1D REDOR/DQF double-filter 13C	312.5 uM [U-13C; U-15N] S7P9 Des-Arg10-Kallidin (DAKD), 312.5 uM not labeled human B1R, 10 mM not labeled AMUPOL, 50 mM not labeled HEPES, 150 mM not labeled NaCl, 4 % w/v not labeled DDM, 0.4 % w/v not labeled CHS	10% H2O/ 40%D2O/ 50% d8-glycerol	175 mM	7.6	1 atm	110	Bruker AVANCE II 400

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE II	400

NMR Refinement
Method	Details	Software
torsion angle dynamics		CYANA
na	used in joint analysis, see paper for more details	TALOS-N
na	used in joint analysis, see paper for more details	PREDITOR
na	used in joint analysis, see paper for more details	Flexible-meccano
na	used in joint analysis, see paper for more details	SHIFTX
na	used in joint analysis, see paper for more details	Circos

NMR Ensemble Information
Conformer Selection Criteria	structures with the least restraint violations
Conformers Calculated Total Number	500
Conformers Submitted Total Number	10
Representative Model	4 (closest to the average)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	structure calculation	CYANA	2.1	Guntert, Mumenthaler and Wuthrich
2	chemical shift assignment	TopSpin		Bruker Biospin
3	collection	TopSpin		Bruker Biospin
4	data analysis	TopSpin		Bruker Biospin
5	processing	TopSpin		Bruker Biospin
6	refinement	CYANA		Guntert, Mumenthaler and Wuthrich
7	refinement	TALOS-N		Shen, Bax
8	refinement	PREDITOR		Berjanskii, Neal, Wishart
9	refinement	Flexible-meccano		Ozone, Bauer, Salmon, Huang, Jensen, Segard, Bernado, Charavay, Blackledge
10	refinement	SHIFTX	1.1	Neal, Nip, Zhang, Wishart
11	refinement	Circos	0.69.3	Krzywinski, Schein, Birol, Connors, Gascoyne, Horsman, Jones, A Marra
12	data analysis	TALOS+		Shen, Delaglio, Cornilescu, Bax

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.